MedTrace Logo

Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

NCT00190580 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2015-03-31

No results posted yet for this study

Summary

The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added to conventional antihypertensive therapy.

Conditions

Interventions

DRUG

valsartan

valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs

DRUG

Conventional antihypertensive drugs

Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers

Sponsors & Collaborators

  • Tokai University

    collaborator OTHER

  • Yokohama City University

    collaborator OTHER

  • Showa University

    collaborator OTHER

  • Kitasato University

    collaborator OTHER

  • St. Marianna University School of Medicine

    collaborator OTHER

  • KVT-Study Group

    lead OTHER

Principal Investigators

  • Kenjiro Kimura, MD, PhD · St. Marianna University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00190580 on ClinicalTrials.gov